TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05542355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral EXL01 matching placebo once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
Study: NCT05640674
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opioid
Study: NCT05062239
Drug: Discontinuance of treatment with statins 7 to 14 days prior to surgery until 30 days postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuance of prior statin therapy
Study: NCT05062239
Drug: No-intervention.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuance of prior statin therapy
Study: NCT04452461
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFIRINOX, including: Oxaliplatin 85 mg/m2 IV over 2 hours, Leucovorin 400mg/m2 IV over 2 hours, Irinotecan at 150 mg/m2 IV over 90 min, 5-Fluoruracil continuous infusion of 2400 mg/m2 IV over 46h.
Study: NCT06577532
Drug: ABO2102
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA encoding mutant KRAS neoantigens, administrated intramuscularly
Study: NCT05890053
Drug: HSK16149 40mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK16149 40mg ， orally twice a day, treatment period; 52-weeks fixed dose.
Study: NCT06223828
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg/kg/dose (max dose 500mg) once daily for 3 days
Study: NCT04818346
Drug: INCB054707
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB054707 will be administered once daily
Study: NCT04818346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or INCB054707 will be administered once daily
Study: NCT06393881
Drug: UIC202201
Approvals — FDA: no, EMA: no, PMDA: no
Description: take UIC202201 once a day for 7 days
Study: NCT06010589
Drug: DWJ1558
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWJ1558
Study: NCT05380934
Drug: TQH3821 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQH3821 tablets is an Interleukin-1 receptor-associated kinase 4 inhibitor that exhibits a high degree of inhibitory activity against IRAK4 kinase.
Study: NCT05380934
Drug: TQH3821 tablets (Placebo)
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQH3821 tablets (Placebo) is a placebo produced with reference to TQH3821 tablets, which has no effect on IRAK4 kinase.
Study: NCT05380934
Drug: Methotrexate tablets
Normalized name: Methotrexate Tablets
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate tablets is a folic acid antagonist, which belongs to an anti-rheumatic drug to improve the condition
Study: NCT05713318
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray daily doses of placebo 4 times added on SOC for 6 consecutive days.
Study: NCT05713318
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray daily doses of placebo 8 times added on SOC for 6 consecutive days.
Study: NCT06171113
Drug: GSK4024484C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses administrated orally with 240 mL of water.
Study: NCT06171113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses administrated orally with 240 mL of water.
Study: NCT06091189
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The initial drink in the alcohol condition will contain 0.3 g/kg (males) or 0.2 g/kg (females) of 80-proof ethanol, adjusted for body weight, and subsequent drinks will contain 0.1 g/kg of ethanol. None of the control (placebo) drinks will contain ethanol.
Study: NCT04952545
Drug: ALXN2050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet.
Study: NCT04952545
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet.
Study: NCT06170372
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen-air mixture without NO 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days
Study: NCT05497284
Drug: LTP001
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTP001 will be administered once daily in the morning
Study: NCT05497284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to LTP001 will be administered once daily in the morning
Study: NCT05497284
Drug: Standard of Care (SoC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nintedanib, pirfenidone, or neither
Study: NCT04788108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT05829616
Drug: QLS12004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be treated with different dose groups of QLS12004 according to the frequency and periodicity of administration as specified in the protocol, until disease progression or unacceptable toxicity.
Study: NCT05116540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline
Study: NCT03972124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft-gel capsules containing placebo
Study: NCT06433180
Drug: Administration of the sham (PLACEBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, capsulized, frozen capsules without fecal matter but containing cryopreservation solution will be administered at the same volume and same time point as in the experimental group. Taken in one day in two separate meals. Administration of the sham after colon cleaning.
Study: NCT06300008
Drug: cetylated fatty acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: use approximately 3 cm long of cream per each side of knee, then apply on the operated knee until completely absorb
Study: NCT06300008
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: use approximately 3 cm long of cream per each side of knee, then apply on the operated knee until completely absorb
Study: NCT00093678
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03762395
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 weeks of treatment with orally administered matching placebo (to 150 mg/day of CXA-10)
Study: NCT06138574
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil
Study: NCT04589819
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be a sugar solution of the manufacturer's design.
Study: NCT06553066
Drug: Deep neuromascular blockage
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: maintenance of a deep neuromuscular block with rocuronium, titrated to maintain a TOF count of 0, and a PTC between 1-2.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale(Leiden scale : 1 indicates extremely poor conditions, 2 poor conditions, 3 acceptable conditions, 4, good conditions and 5 optimal conditions)
Study: NCT04936282
Drug: Grafalon
Approvals — FDA: no, EMA: no, PMDA: no
Description: When Borderline lesions are present in protocol biopsy, administer Grafalon ® 6 mg/kg/day in a single day. Then continue with the normal treatment: Steroids (5 mg/day), tacrolimus (0.1 mg/kg/day) and mycophenolate (1000 mg/day).
Study: NCT04936282
Drug: Normal Treatment
Normalized name: Normaloe
Approvals — FDA: no, EMA: no, PMDA: no
Description: When Borderline lesions are present in protocol biopsy, administer the normal treatment: Steroids (5 mg/day), tacrolimus (0.1 mg/kg/day) and mycophenolate (1000 mg/day)
Study: NCT06553066
Drug: Moderate neuromascular blockage
Approvals — FDA: no, EMA: no, PMDA: no
Description: maintenance of a moderate neuromuscular block with rocuronium, titrated to maintain a TOF count of 1-2
Study: NCT06555237
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopiramide and Beta blockers orally
Study: NCT04608474
Drug: Statins (Cardiovascular Agents)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previously prescribed statin therapy.
Study: NCT04994444
Drug: Nicoderm CQ 21Mg/24Hr Transdermal System
Normalized name: Nicoderm CQ 21mg/24hr Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicoderm CQ patch started 3 weeks prior to quit date. Starting on quit date, patch/gum or patch/lozenge will be used for 8 weeks. Patch will be tapered over the 8 week period.
Study: NCT05127421
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream applied twice a day (BID) to affected areas
Study: NCT06394518
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo for TNP-2092 active drug
Study: NCT04274166
Drug: secukinumab 150 mg (2 injections per dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: secukinumab 150 mg (2 injections per dose
Study: NCT06019936
Drug: MT2004 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.
Study: NCT06019936
Drug: MT2004 Capsule Placebo
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 Capsule Placebo (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.
Study: NCT05403541
Drug: Matching Placebo SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05705570
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 60mg/Kg on day -6
Study: NCT06161844
Drug: Ozempic®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: Ozempic Injectable Product
Study: NCT05084196
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin 5 mg capsule by mouth at bedtime
Study: NCT04626791
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04626791
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05388903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT05388903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05665777
Drug: Qingyan Lihou Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine granules
Study: NCT06316362
Drug: SMOF lipid 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMOF 20%; a blend of (soybean oil, medium chain triglycerides, olive and fish oil) is a new lipid emulsion product that was provided as a bolus dose of 1.5ml/kg for one hour, followed by a maintenance dose of 6 ml/kg for a period of four hours to the active comparator group
Study: NCT04647526
Drug: [Lu-177]-PNT2002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to Arm A will receive 6.8 GBq (±10%) of \[Lu-177\]-PNT2002 every 8 weeks for 4 cycles
Study: NCT04633057
Drug: NordiFlex
Normalized name: Norditropin Nordiflex Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive Recombinant Human Somatropin Injection 0.034 mg/kg once a day, until 52 weeks back site, investigator evaluate effectiveness and safety.
Study: NCT06256783
Drug: Baozhu Keli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once enrolled, participants will be administrated Baozhu Keli
Study: NCT04755712
Drug: Rachianesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of different anesthesia drugs in accordance with the courant practice (mixture of bupivacaine and sufentanil)
Study: NCT05429177
Drug: QY101 ointment or vehicle
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: QY101 ointment or vehicl topical applied to skin
Study: NCT06372821
Drug: NIO752
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antisense oligonucleotide
Study: NCT06476717
Drug: Antirejection therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive standard antirejection therapy according to center protocol.
Study: NCT05542576
Drug: AMDX2011P
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMDX2011P single bolus injection intravenous for diagnostic review
Study: NCT05051865
Drug: SHR1020
Approvals — FDA: no, EMA: no, PMDA: no
Description: camrelizumab combined with SHR1020 for advanced melanoma
Study: NCT05823012
Drug: levothyroxine sodium
Normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine sodium 10 mg/mL
Study: NCT05480566
Drug: Daily medical treatment (e.g., oxygen, medrol, duovent, azitromycine)
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with daily medication prescribed by the physician, which can include oxygen, medrol, duovent, azitromycine or other medications that physicians consider that are needed.
Study: NCT03745664
Drug: Saline Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: During hospitalization, 2 ml of Saline Solution for Injection will be given intravenously twice a day (2 ml every 12 hours).
Study: NCT05568888
Drug: BE1116
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-Factor Prothrombin Complex administered by intravenous (IV) infusion
Study: NCT05568888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by IV infusion
Study: NCT06067412
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efficacy in fits
Study: NCT06669390
Drug: NG11-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG11-2 dose level will vary from 0.92 mg/mL to 5.5 mg/mL during the dose escalation process. The NG11-2 is given as an oral rinse.~Throughout the radiotherapy regimen, no more than 60 minutes prior to the completion of radiotherapy, on each weekday the patient will rinse their mouth with 12.5 ml of NG11-2 for between 90 \& 120 seconds duration, gargling twice for approximately three seconds each if possible during this period then expectorate the solution.
Study: NCT06670898
Drug: [14C] NS-580
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension
Study: NCT06670274
Drug: HC002 MAD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part 2 will enroll 24 participants across 3 cohorts.~Route of administration: Oral Dose interval and frequency: Once daily for 7 days
Study: NCT06670274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered across SAD and MAD
Study: NCT06668987
Drug: B10 L-BPA Injection
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational product is B10 L-BPA Injection, is a boron-containing compound in which 10B replaces a position on L-phenylalanine at the para position with dihydroxyboron.
Study: NCT05445011
Drug: Fludarabine + Cyclophosphamide + TAA05 Cell Injection
Normalized name: fludarabine Injection
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine + Cyclophosphamide + TAA05 Cell Injection Fludarabine 25 mg/kg \* 3d on day-7\~-2; Cyclophosphamide 250 mg/kg \*3d on day-7\~-2; TAA05 Cell Injection on day 0.
Study: NCT05667727
Drug: nebulized epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: we are using 1:1000 epinephrine into nebulization form
Study: NCT06281886
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral capecitabine 1000 mg/m2, twice daily, on days 1-14, every 3 weeks, concurrently with radiotherapy
Study: NCT05501860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Sterile Topical Ophthalmic Solution
Study: NCT05449613
Drug: acupoint application
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the trial, if patients can not tolerate the pain, meloxicam tablets can be added temporarily, and the total amount of medication for each patient during the observation period was recorded.
Study: NCT04389580
Drug: Drug: Isotretinoin plus Tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg PO (by mouth) twice daily for 14 days~13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days starting after three days of taking tamoxifen
Study: NCT04389580
Drug: Aerosolized Isotretinoin plus Tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg PO (by mouth) twice daily for 14 days~Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days starting after three days of taking tamoxifen
Study: NCT06128590
Drug: Mepivacaine hydrochloride in combination with epinephrine
Normalized name: epinephrine / mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The anesthetic of choice will be Mepivacaine, which is widely used in dentistry with duration between 1.5 and 2 minutes. The maximum recommended dose is 6.6 mg/Kg, not exceeding 400 mg or 11 anesthetic tubes.~It is a sterile injectable solution of 2% mepivacaine hydrochloride (20 mg/mL) in combination with epinephrine 1:100,000 (0.01 mg/mL). Each vial contains 1.8 mL, 36 mg of mepivacaine hydrochloride, and 0.018 mg of epinephrine. All patients will use anesthetics from the same brand (DLA Pharmaceutical LTDA), one of the most widely used on the market. All patients will be anesthetized with tubes from the same batch, one tube per procedure.
Study: NCT05611359
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT04997174
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in ERAS group received celecoxib
Study: NCT05876065
Drug: XC
Normalized name: Excof
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (bid po, d1-14) and cyclophosphamide (qd po, d1-d14) every 21 days
Study: NCT04831736
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Study: NCT05498259
Drug: CHOP-like Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclophosphamide, anthracene nucleus chemotherapeutics（doxorubicin，liposomal doxorubicin, etc.）, vinca alkaloids（vincristine, vindesine, etc.），and glucocorticoid （dexamethasone，prednison, etc.）.
Study: NCT05020639
Drug: TQB3820 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3820 is a novel cereblon-modulating agent.
Study: NCT04916470
Drug: Placebo (Semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly for 52 weeks.
Study: NCT06580574
Drug: PD1/PDL1 antibody monotherapy, up to 24 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-specific, according to Drug Instructions
Study: NCT05800392
Drug: DEC103
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is composed by two medications: An active sublingual pill and an active oral one.
Study: NCT05800392
Drug: Placebo DEC103
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is composed by two medications: A placebo sublingual pill and an placebo oral one.
Study: NCT05846516
Drug: ATP150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT05846516
Drug: ATP152
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT05120934
Drug: Placebo 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg tablet with no active study ingredient for 4 weeks
Study: NCT05120934
Drug: Placebo 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg tablet with no active study ingredient for 4 weeks
Study: NCT04673617
Drug: AB-101
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK cell therapy
Study: NCT04673617
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepleting chemotherapy
Study: NCT05160558
Drug: BIIB132
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT06180824
Drug: Gelafundin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin will be diluted with gelafundin colloid fluid in 50mls syringe and tubing (same product manufacturer).~Blood glucose level will be taken from arterial line at presentation or prior to start insulin and checked using glucometer. Then, at 2 hour and 6 hours after initiation of treatment.
Study: NCT05234684
Drug: Placebo + R-CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is a white, round, uncoated tablet. The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.
Study: NCT05528120
Drug: VC004 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration after fasting/high-fat meal
Study: NCT05528120
Drug: VC004 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration after high-fat/fasting meal
Study: NCT06173778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active medication, self-administered
Study: NCT05710068
Drug: Combination cream
Normalized name: SUNSCREEN-35 PABA-FREE COMBINATION CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% hydroquinone, 0.003% tretinoin, and 1% hydrocortisone twice daily for 2 months
Study: NCT06100042
Drug: BDP/FF/G
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF/G is an extrafine single inhaler triple therapy available in two dosage strengths:~* Medium strength (MS) containing 100 µg of beclomethasone dipropionate, 6 µg of formoterol fumarate dihydrate and 10 µg of glycopyrronium (as 12.5 µg glycopyrronium bromide);~* High strength (HS) containing 200 µg of beclomethasone dipropionate, 6 µg of formoterol fumarate dihydrate and 10 µg of glycopyrronium (as 12.5 µg glycopyrronium bromide).
Study: NCT05149274
Drug: DWP14012 Tablet A
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 10mg
Study: NCT05149274
Drug: DWP14012 Tablet B
Normalized name: ACTION B-100 TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 40mg
Study: NCT05556863
Drug: ELA026
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ELA026